<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430558</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00002-47</org_study_id>
    <nct_id>NCT02430558</nct_id>
  </id_info>
  <brief_title>Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft</brief_title>
  <acronym>ODPHOENIX2</acronym>
  <official_title>Second Line Treatment of Knee Osteochondral Lesion With Decellularized Treated Osteochondral Allograft. Phase IIa Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TBF Genie Tissulaire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TBF Genie Tissulaire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with IKDC score &lt; 65, pretreated with mosaicplasty or ACI ( with matrix or not)&#xD;
      within &gt; 18 months, with one or two osteochondral lesions are recruited to have treated&#xD;
      osteochondral allografts in mosaicplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of IKDC score</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recellularization of tissue (arthroscopy and histology)</measure>
    <time_frame>18 months</time_frame>
    <description>arthroscopy and histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>integration of the tissue by imagery</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cartilage Injury</condition>
  <arm_group>
    <arm_group_label>OD-PHOENIX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of 1 to 5 osteochondral allograft cylinders in mosaic</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OD-PHOENIX</intervention_name>
    <description>dellelularized, freeze-dried, irradiated osteochondral allograft</description>
    <arm_group_label>OD-PHOENIX</arm_group_label>
    <other_name>osteochondral allograft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients between the ages of 18 and 55&#xD;
&#xD;
               -  osteochondral lesions of the knee due to trauma or osteochondritis dissecans or&#xD;
                  removal treatment ( lesion post autograft)&#xD;
&#xD;
               -  Osteochondral lesion &gt; grade II- ICRS&#xD;
&#xD;
               -  One lesion or 2 concomitant lesions (tibial plateau, patella and condyles )at&#xD;
                  least one lesion has been pretreated by mosaicplasy or ACI. These treatment would&#xD;
                  have to have been made at least 18 months before inclusion&#xD;
&#xD;
               -  Presence of disabling and clinically meaningful symptoms (subjective IKDC &lt; 65,&#xD;
                  no improvement for 3 months)&#xD;
&#xD;
               -  No significant obesity (BMI &lt; 30)&#xD;
&#xD;
               -  Accompanying ligamentous and meniscal lesions, joint malalignment and patella&#xD;
                  femoral instability are authorized and corrected concurrently.&#xD;
&#xD;
               -  Patient able to understand, sign and date the informed consent form&#xD;
&#xD;
               -  Patient affiliated with a national health insurance system or who is the&#xD;
                  beneficiary of such as system&#xD;
&#xD;
               -  Women of childbearing age may not be included in the clinical trial unless their&#xD;
                  pregnancy test is negative. If this test is negative, they will be asked to use&#xD;
                  an effective birth control method during the entire the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnant or breast feeding women: Women of childbearing age will be asked to undergo&#xD;
             a pregnancy test before being enrolled into the study and to use an effective birth&#xD;
             control method.&#xD;
&#xD;
          -  Presence of osteoarthritis, rheumatoid arthritis, any other condition of knee joint&#xD;
             that, in the surgeon's opinion, is likely to compromise the allograft's outcome&#xD;
&#xD;
          -  Excessive laxity or recurrent instability that could affect the score evaluation&#xD;
             without concomitant ligamentoplasty&#xD;
&#xD;
          -  Presence of an ulcerative disease, heavy smoking, tuberculosis, chronic psychiatric&#xD;
             disorder or disease requiring long-term treatment with a medication that would affect&#xD;
             bone or joint metabolism&#xD;
&#xD;
          -  Persons with cancer or a history of cancer&#xD;
&#xD;
          -  Persons deprived of their freedom by a judicial or administrative decision&#xD;
&#xD;
          -  Adults subject to legal protection measures or who are unable to provide their consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Barnouin, MD</last_name>
    <email>laurence.barnouin@tbf-lab.com</email>
  </overall_contact>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

